Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure

NCT03727828 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2020-01-09

No results posted yet for this study

Summary

The objective of this work is to investigate and then to sequence new biomarkers in the blood of patients with heart failure, and study their diagnostic, risk stratification and prognostic value.

Conditions

Interventions

DIAGNOSTIC_TEST

Patients with heart failure

Participants will have serial blood collection on medical therapy for heart failure

Sponsors & Collaborators

  • Tongji Hospital

    collaborator OTHER
  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER
  • Nanfang Hospital, Southern Medical University

    collaborator OTHER
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER
  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER
  • Yangpu Hospital

    collaborator UNKNOWN
  • Shanghai Municipal Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Huashan Hospital Baoshan Branch

    collaborator UNKNOWN
  • Shanghai Zhongye Hospital

    collaborator UNKNOWN
  • Shanghai BaoshanLuodianHospital

    collaborator UNKNOWN
  • Shanghai Shibei Hospital

    collaborator UNKNOWN
  • Nantong Sixth People's Hospital

    collaborator UNKNOWN
  • Shanghai 10th People's Hospital

    lead OTHER

Principal Investigators

  • Dachun Xu, Ph.D · Shanghai 10th People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2020-12-01
Completion
2021-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03727828 on ClinicalTrials.gov